Foster Victor Wealth Advisors LLC Grows Holdings in Becton, Dickinson and Company $BDX

Key Points

• Foster Victor Wealth Advisors LLC increased its holdings in Becton, Dickinson and Company (BDX) by 40.4%, now owning 39,274 shares valued at approximately $6.89 million.
• Becton, Dickinson recently reported quarterly earnings of $3.68 per share, exceeding estimates, with a revenue increase of 10.4% year-over-year to $5.51 billion.
• The company announced a quarterly dividend of $1.04 per share, representing a yield of 2.2%, with a payout ratio of 74.82%.

Foster Victor Wealth Advisors LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 40.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,274 shares of the medical instruments supplier's stock after acquiring an additional 11,308 shares during the quarter. Foster Victor Wealth Advisors LLC's holdings in Becton, Dickinson and Company were worth $6,893,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Saudi Central Bank purchased a new position in Becton, Dickinson and Company during the first quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $29,000. REAP Financial Group LLC grew its stake in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the period. Finally, Cornerstone Planning Group LLC increased its holdings in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $186.44 on Wednesday. The company has a market capitalization of $53.44 billion, a P/E ratio of 33.53, a PEG ratio of 1.50 and a beta of 0.27. The business has a 50 day simple moving average of $188.00 and a 200-day simple moving average of $189.59. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter last year, the company posted $3.50 earnings per share. Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,965 shares of company stock valued at $551,536 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Wells Fargo & Company upped their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Morgan Stanley increased their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $213.30.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.